Wednesday, Novartis AG (NYSE:NVS) released topline results from twice-yearly Leqvio (inclisiran) in the Phase 3 V-MONO study, which met its primary endpoints.

V-MONO is part of the 60,000-patient VictORION clinical trial program assessing Leqvio for primary and secondary ASCVD prevention.

Also Read: Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal.

Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy.

Ezetimibe is the most commonly used nonstatin agent, which ...